Semaglutide Use in Patients with CKD and a History of Kidney Stones

KDIGO Guideline Recommendations

The 2022 KDIGO guideline recommends GLP‑1 receptor agonists such as semaglutide for adults with type 2 diabetes and chronic kidney disease (eGFR ≥ 30 mL/min/1.73 m²) when metformin and SGLT2 inhibitors are insufficient or contraindicated, citing cardiovascular benefit and renal safety. 4
KDIGO classifies semaglutide as a preferred GLP‑1 RA because of documented cardiovascular outcome benefits in large trials. 2
The guideline emphasizes that semaglutide requires no dose adjustment across all CKD stages, including severe CKD, although data are limited; the recommendation is considered a strong guideline statement. 4

When initiating or escalating semaglutide, clinicians should monitor eGFR, especially in patients who develop severe gastrointestinal adverse effects, to detect any acute changes in renal function. 1
For patients with stage 4 CKD (eGFR 15–29 mL/min/1.73 m²), eGFR should be re‑checked at least every 3–6 months to ensure stability while on therapy. (Guideline‑based recommendation; evidence level moderate) 2

Start semaglutide at 0.25 mg subcutaneously once weekly (injectable) or 3 mg orally once daily, irrespective of renal function, because renal impairment does not affect drug clearance. 2
If tolerated, increase to 0.5 mg weekly after 4 weeks, then to 1.0 mg weekly after an additional 4 weeks to achieve glycaemic targets. 2
For the oral formulation, step up to 7 mg daily after 30 days, and to 14 mg daily after another 30 days if further glycaemic control is needed. 2

A history of urolithiasis (kidney stones) is not a contraindication to semaglutide; the FDA labeling does not list stones as a precaution. 2
Do not reduce semaglutide dose in renal impairment because the drug is cleared mainly by proteolytic degradation (≈ 3 % unchanged in urine). 2
Avoid concomitant use of DPP‑4 inhibitors (e.g., sitagliptin, linagliptin) with semaglutide, as no additive glycaemic benefit has been demonstrated and costs increase. 2

Gastro‑intestinal adverse effects (nausea, vomiting, abdominal pain) are the most common cause of discontinuation; patients should be counseled and dose titrated slowly. (Evidence from trial safety data; moderate) 2
In patients receiving diuretics, monitor for volume depletion, although this risk is more prominent with SGLT2 inhibitors. 2
When semaglutide is added to insulin or sulfonylureas, assess hypoglycaemia risk and consider reducing the dose of the insulin‑secretagogue agents. (Guideline recommendation; moderate) 2